Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triiodothyronine regulates angiogenic growth factor and cytokine secretion by isolated human decidual cells in a cell-type specific and gestational age-dependent manner.

Human reproduction (Oxford, England)·2014
Same author

Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.

The Journal of clinical endocrinology and metabolism·2013
Same author

Expression and function of thyroid hormone transporters in the microvillous plasma membrane of human term placental syncytiotrophoblast.

Endocrinology·2012
Same author

PTTG-binding factor (PBF) is a novel regulator of the thyroid hormone transporter MCT8.

Endocrinology·2012
Same author

Clinical, quality of life, and economic value of acromegaly disease control.

Pituitary·2011
Same author

The expression of thyroid hormone transporters in the human fetal cerebral cortex during early development and in N-Tera-2 neurodifferentiation.

The Journal of physiology·2011
Same journal

Mitochondria produce lactate to vent redox pressure.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Beyond fat storage: neuronal lipid droplets regulate whole-body metabolism.

Trends in endocrinology and metabolism: TEM·2026
Same journal

HDL resuscitates cells from ferroptosis.

Trends in endocrinology and metabolism: TEM·2026
Same journal

2-Methylbutyrylcarnitine (2MBC).

Trends in endocrinology and metabolism: TEM·2026
Same journal

Decoding growth hormone actions on human growth plate stem cells.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Androgen loss backfires: Brain gate for tumor immunity.

Trends in endocrinology and metabolism: TEM·2026
See all related articles

Related Experiment Videos

Amiodarone and thyroid dysfunction.

J A Franklyn1, M C Sheppard

  • 1Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Birmingham, England.

Trends in Endocrinology and Metabolism: TEM
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Amiodarone, an antiarrhythmic drug, alters thyroid hormone levels by inhibiting T4 to T3 conversion. This can lead to euthyroid states, thyrotoxicosis, or hypothyroidism, depending on iodine levels.

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Pharmacology
  • Cardiology

Background:

  • Amiodarone is a critical antiarrhythmic medication with structural similarity to thyroid hormones.
  • Its high iodine content significantly impacts thyroid hormone metabolism.
  • Understanding these effects is crucial for patient management.

Purpose of the Study:

  • To elucidate the biochemical changes in thyroid hormones induced by amiodarone.
  • To investigate the clinical implications of amiodarone on thyroid function.
  • To explore the geographical variations in amiodarone-induced thyroid dysfunction.

Main Methods:

  • Analysis of circulating thyroid hormone concentrations (T4 and T3) in patients treated with amiodarone.
  • Assessment of clinical thyroid status (euthyroid, thyrotoxicosis, hypothyroidism).
  • Correlation of thyroid dysfunction prevalence with regional iodine availability.

Main Results:

  • Amiodarone treatment typically elevates serum thyroxine (T4) and decreases tri-iodothyronine (T3).
  • These hormonal shifts often occur in clinically euthyroid individuals.
  • Overt thyrotoxicosis and hypothyroidism are potential complications, with differing geographic prevalence.

Conclusions:

  • Amiodarone significantly alters thyroid hormone homeostasis.
  • Geographical iodine status influences the type of amiodarone-induced thyroid dysfunction.
  • Careful monitoring of thyroid function is essential during amiodarone therapy.